Yang Hong-Yu, Xia Yu-Qing, Hou Yu-Jia, Xue Peng, Zhu Shi-Jie, Lu Dian-Rong
Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China.
Department of Oncology, Tianjin University of Chinese Medicine, Tianjin 300000, China.
World J Clin Cases. 2024 Jan 16;12(2):405-411. doi: 10.12998/wjcc.v12.i2.405.
Small cell lung cancer (SCLC) is a common and aggressive subtype of lung cancer. It is characterized by rapid growth and a high mortality rate. Approximately 10% of patients with SCLC present with brain metastases at the time of diagnosis, which is associated with a median survival of 5 mo. This study aimed to summarize the effect of bevacizumab on the progression-free survival (PFS) and overall survival of patients with brain metastasis of SCLC.
A 62-year-old man was referred to our hospital in February 2023 because of dizziness and numbness of the right lower extremity without headache or fever for more than four weeks. The patient was diagnosed with limited-stage SCLC. He received 8 cycles of chemotherapy combined with maintenance bevacizumab therapy and achieved a PFS of over 7 mo.
The combination of bevacizumab and irinotecan effectively alleviated brain metastasis in SCLC and prolonged PFS.
小细胞肺癌（SCLC）是肺癌中常见且侵袭性强的一种亚型。其特点是生长迅速且死亡率高。约10%的SCLC患者在诊断时即出现脑转移，这与中位生存期5个月相关。本研究旨在总结贝伐单抗对SCLC脑转移患者无进展生存期（PFS）和总生存期的影响。
一名62岁男性于2023年2月因右下肢头晕和麻木4周余，无头痛或发热症状转诊至我院。该患者被诊断为局限期SCLC。他接受了8周期化疗联合贝伐单抗维持治疗，无进展生存期超过7个月。
贝伐单抗联合伊立替康可有效缓解SCLC脑转移并延长无进展生存期。
